What Are Chronic Lower Respiratory Diseases?

Chronic lower respiratory diseases are a group of long-lasting conditions that damage the airways and other structures of the lungs, making it progressively harder to breathe. The group includes chronic obstructive pulmonary disease (COPD), asthma, bronchiectasis, and several rarer conditions like pulmonary fibrosis. Collectively, they ranked as the third leading cause of death worldwide in 2017, accounting for about 7% of all deaths globally, behind only cardiovascular diseases and cancer.¹ Despite a decline in death rates when age and population growth are factored in, the raw number of people affected keeps climbing, and the conditions remain stubbornly undertreated in much of the world.

The Diseases Under the Umbrella

The phrase “chronic lower respiratory diseases” is a classification term used in mortality statistics and public health reporting. It bundles together several distinct conditions that share a key feature: they impair airflow or gas exchange in the lungs over months or years, rather than resolving quickly like a bout of pneumonia. The two biggest contributors by far are COPD and asthma.

COPD itself is not one disease but a combination of overlapping problems. Chronic bronchitis involves persistent inflammation and excess mucus production in the larger airways, with enlargement of the mucus-producing glands in the airway walls. Small airways disease involves inflammation and scarring of the tiny bronchioles deeper in the lungs. Emphysema involves the destruction of the walls of the alveoli, the tiny air sacs where oxygen enters the blood, leading to permanent loss of lung tissue.² Most people with COPD have some combination of all three.

Asthma is different in character. It tends to be more episodic, with flare-ups of wheezing, chest tightness, and breathlessness triggered by allergens, exercise, cold air, or infections. The airway narrowing in asthma is largely reversible between episodes, at least in milder cases, whereas COPD involves damage that does not bounce back. The underlying inflammation also differs: asthma is driven primarily by immune cells called eosinophils and a cascade of signaling molecules known as type 2 cytokines, which produce the hallmark features of allergic airway inflammation and airway hypersensitivity.³ COPD inflammation, by contrast, is dominated by different immune cell types, including neutrophils and a subset of lymphocytes (CD8+ T cells) rather than the CD4+ lymphocytes and eosinophils that predominate in asthma.⁴

Other conditions in the chronic lower respiratory disease category include bronchiectasis, where the airways become permanently widened and prone to repeated infections, and various forms of interstitial lung disease that scar or thicken lung tissue. Occupational lung diseases caused by years of inhaling dust or chemical fumes also fit here, as does cystic fibrosis, a genetic condition that causes thick, sticky mucus to clog the lungs.

How Many People Are Affected

In 2017, roughly 545 million people worldwide had a chronic respiratory disease, an increase of nearly 40% compared with 1990. Deaths from these conditions rose by 18% over the same period, climbing from about 3.3 million to just under 3.9 million per year.⁵ Those raw numbers look alarming, but they need context. The world’s population grew substantially during those decades, and it aged. When researchers adjusted for age and population size, the death rate actually fell by more than 40%, and the rate of disability dropped by about 38%.⁵ In other words, any given person’s risk of dying from a chronic lung disease has dropped considerably, but there are more people alive and more older people, so total deaths still crept upward.

The age-standardised mortality rate declined by an average of about 2.4% per year between 1990 and 2017.⁶ That progress is real but uneven. In wealthy countries with strong tobacco-control policies, smoking-related COPD has plateaued or fallen. In lower-income settings, household air pollution from cooking fuels, outdoor air pollution, and limited access to inhalers continue to drive high rates of disease and death.

What Causes Them

Smoking remains the dominant risk factor for COPD in high-income countries. Decades of inhaling cigarette smoke triggers the inflammation, mucus overproduction, and tissue destruction that define the disease. But smoking does not explain the whole picture. Worldwide, a large share of COPD cases occur in people who have never smoked.

Burning wood, animal dung, crop residue, or charcoal for cooking and heating exposes billions of people to household air pollution. Long-term exposure to biomass smoke is strongly linked to COPD, chronic bronchitis, and other lung damage, and in many low-income countries it may rival tobacco as a cause.⁷ Outdoor air pollution adds another layer of risk, with evidence that long-term exposure to high concentrations of pollutants can both increase the incidence of COPD and worsen existing disease.⁸

Genetic factors matter too. Alpha-1 antitrypsin deficiency is a hereditary condition in which the body does not produce enough of a protein that shields lung tissue from damage by enzymes released during normal immune activity. Without that shield, lung tissue breaks down over time, leading to emphysema that typically shows up in a person’s thirties or forties, especially if they also smoke.⁹ The condition is often missed for years because doctors may not test for it unless emphysema appears unusually early or in a non-smoker.

Asthma has its own set of triggers and risk factors, many of them rooted in allergic sensitization. Family history, childhood respiratory infections, exposure to allergens like dust mites or mold, and air pollution all play roles. In some people, asthma that begins in childhood remains mild; in others, it becomes severe and persistent.

Seeds Planted in Childhood

One finding that often surprises people is how early these diseases can begin to take shape. Lung function is not something you simply have and then lose. You build it through childhood and adolescence, reaching a peak in your mid-twenties, and it declines gradually from there. Anything that prevents you from reaching your full peak — premature birth, severe childhood respiratory infections, heavy exposure to tobacco smoke in the home, or poorly controlled childhood asthma — can leave you starting adult life with less lung capacity to spare.

A study tracking lung function from infancy through early adulthood found that children on a persistently low lung function trajectory were more likely to have had recurrent wheezing with severe exacerbations, early allergic sensitization, and exposure to tobacco smoke.¹⁰ Other research has found that children with severe asthma face dramatically higher odds of developing COPD in adulthood, with one analysis showing an odds ratio of 32 compared to controls.¹¹ That does not mean every child with asthma will develop COPD, but it does underscore that chronic lung disease is not exclusively an old person’s problem with a simple smoking cause.

Exacerbations and Why They Matter

For people living with COPD or severe asthma, the background state of reduced lung function is punctuated by episodes called exacerbations — sudden, often dramatic worsening of symptoms. You might picture it as the difference between walking with a limp and having your bad leg give out entirely. Exacerbations send people to the emergency department, land them in the hospital, and each one can permanently ratchet down lung function a notch further.

Respiratory infections are the most common trigger. In one study of patients hospitalized for severe COPD exacerbations, about 61% had a respiratory infection, with pneumonia accounting for most of those cases. Among infections where the cause was identified, roughly a third were viral, a third were bacterial, and about 12% were mixed.¹² Viruses and bacteria infect the lower airway and amplify the inflammation that is already there, overwhelming the lungs’ already compromised defenses.¹³

Air pollution spikes, cold weather, and abrupt changes in humidity can also trigger exacerbations. For people with asthma, allergen exposure is an additional culprit. The frequency of exacerbations varies enormously from person to person. Some people go years between serious flare-ups; others cycle through them every few months. Reducing exacerbation frequency is one of the central goals of treatment, because each episode carries a real cost in lung function that does not fully recover.

How These Diseases Are Treated

There is no cure for COPD. Once lung tissue is destroyed, current medicine cannot regenerate it. The aim of treatment is to slow the decline, relieve symptoms, and prevent exacerbations. For asthma, the picture is somewhat brighter: most cases can be well controlled with the right medication, though a subset of patients with severe disease remains difficult to manage.

The foundation of both COPD and asthma management is inhaled medication. Bronchodilators relax the muscles around the airways, opening them up. Inhaled corticosteroids reduce inflammation. In one trial comparing these approaches in patients with obstructive airways disease, those on inhaled corticosteroids saw their lung function improve by about 10% of predicted value within three months, while bronchodilator-only and placebo groups showed no change.¹⁴ In practice, many patients use both types of medication together.

For severe asthma that does not respond adequately to standard inhalers, biologic therapies have become a major advance. These are injectable drugs designed to block specific molecules in the inflammatory cascade. Options now include antibodies that target IgE (the molecule driving allergic reactions), antibodies that target interleukin-5 (the signal that keeps eosinophils alive and active), and antibodies that block the interleukin-4/interleukin-13 pathway. Use of these targeted treatments has led to meaningful reductions in asthma symptoms, fewer exacerbations, and improved lung function in many patients.¹⁵ They are expensive, though, and their availability in lower-income countries remains limited.

Pulmonary rehabilitation is one of the most effective interventions for COPD and one of the most underused. Programs typically run six to eight weeks and combine supervised exercise training with education and psychological support. A Cochrane review of the evidence found that rehabilitation produced significant improvements in breathlessness, fatigue, and patients’ sense of control over their disease.¹⁶ Even patients with multiple other health problems can safely participate and see clinically meaningful gains in exercise capacity and overall health status.¹⁷ Despite the strong evidence, referral rates remain low. Many patients are never offered the option, and many who are enrolled drop out.

For people with advanced disease whose blood oxygen levels fall dangerously low, supplemental oxygen at home becomes necessary. The most common reason for home oxygen therapy is respiratory failure from COPD, and patients typically need to use it for 16 hours a day or more to see a survival benefit.¹⁸ Some patients also use non-invasive ventilation devices that help push air into the lungs, particularly during sleep.

The Mental Health Burden

Chronic breathlessness does not just wear on the lungs. It grinds down mental health in ways that often go unrecognized by the medical system. Depression and anxiety are common in people with COPD, and the combination is vicious: psychiatric problems reduce treatment adherence, lower physical activity, and diminish quality of life, which in turn leads to more frequent and more severe exacerbations, more hospitalizations, and higher mortality.¹⁹

Research has found that anxiety, depression, and panic attacks in COPD patients correlate with disease severity and poorer quality of life regardless of whether the person currently smokes.²⁰ The panic attacks are worth highlighting because they can feel indistinguishable from a COPD exacerbation: sudden breathlessness, chest tightness, racing heart. Patients may rush to the emergency room convinced they are having a medical crisis, or they may stay home during a genuine exacerbation assuming it is “just” a panic attack. Despite the high prevalence of these problems and their clear impact on outcomes, remarkably few clinical trials have tested treatments for depression and anxiety specifically in this population.¹⁹

Cardiovascular disease is another major companion. There is growing recognition that the inflammation present in COPD is not limited to the lungs but spills into the systemic circulation and can affect the heart and blood vessels.²¹ People with COPD are at elevated risk for heart attack, stroke, and heart failure, and cardiovascular events are a leading cause of death in this population, sometimes even exceeding the lungs as the thing that actually kills them.

Access to Inhalers Around the World

If you live in a high-income country, you probably take for granted that a basic rescue inhaler is available at any pharmacy. That is far from the reality in much of the world. A systematic review of inhaler availability in low- and middle-income countries found stark gaps: only six of 58 countries surveyed met the 80% availability target for short-acting rescue inhalers, only three of 48 met it for inhaled corticosteroids, and none of the countries surveyed had adequate availability of combination inhalers containing both a corticosteroid and a long-acting bronchodilator.²²

Even where inhalers are available, they may be unaffordable. In some settings, treating severe COPD costs several days’ wages per month, and combination inhalers carry markedly inflated prices relative to international reference prices.²³ Limited access to affordable inhaled medicines causes avoidable sickness and death on a massive scale.²⁴ This is one of the great inequities in global health: the disease burden is shifting toward low-income countries, but the treatments remain concentrated in wealthy ones.

Regenerative Medicine and What Comes Next

Because COPD involves the irreversible destruction of lung tissue, researchers have long searched for ways to reverse the damage rather than simply manage symptoms. Stem cell therapy is the most talked-about frontier. The idea is that transplanted stem cells, which have the capacity to renew themselves and develop into specialized cell types, might repair damaged airways and alveoli.²⁵

Recent work has focused on airway basal stem cells, a specific population of cells that sit at the base of the airway lining and are capable of regenerating the different cell types that make up that lining. Early research suggests these cells can repair airway damage caused by environmental exposures and even genetic disorders like cystic fibrosis.²⁶ Another approach involves building bioartificial lung tissue on scaffolds. Researchers strip a donor lung of its cells, leaving behind the organ’s natural architecture as a framework, then seed that framework with the patient’s own cells to try to grow functional tissue.²⁷

All of these approaches remain experimental. Stem cell clinics marketing lung treatments directly to patients have gotten ahead of the science, and no stem cell therapy for COPD or pulmonary fibrosis has been approved by major regulatory agencies. The research is promising in a long-term, foundational sense, not in a “this will be available at your doctor’s office next year” sense. For now, the interventions that actually save lives are less glamorous: quitting smoking, getting vaccinated against flu and pneumococcal disease, using inhalers correctly and consistently, staying active, and making sure that pulmonary rehabilitation is offered to everyone who could benefit from it.